As of 2026-03-19, the Relative Valuation of C4 Therapeutics Inc (CCCC) is (25.12) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.69 USD, the upside of C4 Therapeutics Inc based on Relative Valuation is -1034.0%.
The range of the Relative Valuation is (23.03) - (28.86) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.4x - 28.1x | 24.6x |
| Forward P/E multiples | 21.3x - 26.8x | 22.1x |
| Fair Price | (23.03) - (28.86) | (25.12) |
| Upside | -956.0% - -1172.8% | -1034.0% |
| Date | P/E |
| 2026-03-18 | -2.50 |
| 2026-03-17 | -2.57 |
| 2026-03-16 | -2.54 |
| 2026-03-13 | -2.53 |
| 2026-03-12 | -2.56 |
| 2026-03-11 | -2.78 |
| 2026-03-10 | -2.90 |
| 2026-03-09 | -3.34 |
| 2026-03-06 | -2.83 |
| 2026-03-05 | -2.82 |
| 2026-03-04 | -2.87 |
| 2026-03-03 | -2.74 |
| 2026-03-02 | -2.95 |
| 2026-02-27 | -2.51 |
| 2026-02-26 | -2.58 |
| 2026-02-25 | -2.57 |
| 2026-02-24 | -2.22 |
| 2026-02-23 | -2.14 |
| 2026-02-20 | -2.01 |
| 2026-02-19 | -1.97 |
| 2026-02-18 | -1.78 |
| 2026-02-17 | -1.70 |
| 2026-02-13 | -1.76 |
| 2026-02-12 | -1.70 |
| 2026-02-11 | -1.70 |
| 2026-02-10 | -1.71 |
| 2026-02-09 | -1.65 |
| 2026-02-06 | -1.69 |
| 2026-02-05 | -1.59 |
| 2026-02-04 | -1.76 |
| 2026-02-03 | -1.87 |
| 2026-02-02 | -1.75 |
| 2026-01-30 | -1.77 |
| 2026-01-29 | -1.82 |
| 2026-01-28 | -1.89 |
| 2026-01-27 | -1.99 |
| 2026-01-26 | -1.92 |
| 2026-01-23 | -2.00 |
| 2026-01-22 | -2.03 |
| 2026-01-21 | -1.97 |
| 2026-01-20 | -2.03 |
| 2026-01-16 | -2.07 |
| 2026-01-15 | -2.06 |
| 2026-01-14 | -2.17 |
| 2026-01-13 | -2.15 |
| 2026-01-12 | -1.98 |
| 2026-01-09 | -1.99 |
| 2026-01-08 | -2.04 |
| 2026-01-07 | -2.06 |
| 2026-01-06 | -1.89 |